

Andrew A Somogyi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9469253/publications.pdf>

Version: 2024-02-01

182
papers

8,065
citations

43973

48
h-index

56606

83
g-index

184
all docs

184
docs citations

184
times ranked

6749
citing authors

#	ARTICLE	IF	CITATIONS
1	Morphine activates neuroinflammation in a manner parallel to endotoxin. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6325-6330.	3.3	401
2	Pharmacogenetics of Opioids. Clinical Pharmacology and Therapeutics, 2007, 81, 429-444.	2.3	298
3	Hyperalgesic responses in methadone maintenance patients. Pain, 2001, 90, 91-96.	2.0	272
4	Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain, Behavior, and Immunity, 2008, 22, 1178-1189.	2.0	262
5	Drug Interactions with Cimetidine. Clinical Pharmacokinetics, 1982, 7, 23-41.	1.6	243
6	Mu receptor binding of some commonly used opioids and their metabolites. Life Sciences, 1991, 48, 2165-2171.	2.0	223
7	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2D6</i> , <i>OPRM1</i> , and <i>COMT</i> Genotypes and Select Opioid Therapy. Clinical Pharmacology and Therapeutics, 2021, 110, 888-896.	2.3	212
8	The Disposition of Morphine and Its 3- and 6-Glucuronide Metabolites in Humans and Animals, and the Importance of the Metabolites to the Pharmacological Effects of Morphine. Drug Metabolism Reviews, 1996, 28, 345-472.	1.5	190
9	Pharmacokinetic Interactions of Cimetidine 1987. Clinical Pharmacokinetics, 1987, 12, 321-366.	1.6	185
10	Does Intraoperative Ketamine Attenuate Inflammatory Reactivity Following Surgery? A Systematic Review and Meta-Analysis. Anesthesia and Analgesia, 2012, 115, 934-943.	1.1	178
11	Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. Journal of Pain and Symptom Management, 1996, 12, 182-189.	0.6	161
12	Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. British Journal of Clinical Pharmacology, 1999, 47, 403-412.	1.1	161
13	Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain, 2001, 93, 155-163.	2.0	149
14	Clinical Pharmacokinetics of Cimetidine. Clinical Pharmacokinetics, 1983, 8, 463-495.	1.6	143
15	Hyperalgesia in Opioid-Managed Chronic Pain and Opioid-Dependent Patients. Journal of Pain, 2009, 10, 316-322.	0.7	141
16	ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clinical Pharmacology and Therapeutics, 2006, 80, 682-690.	2.3	132
17	Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clinical Pharmacology and Therapeutics, 1999, 65, 685-694.	2.3	119
18	The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans*. Clinical Pharmacology and Therapeutics, 1996, 60, 295-307.	2.3	115

#	ARTICLE	IF	CITATIONS
19	CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 287-297.	1.1	112
20	Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 427-440.	1.1	110
21	PharmVar GeneFocus: <i>CYP2B6</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 82-97.	2.3	108
22	Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. <i>Journal of Pain and Symptom Management</i> , 1997, 14, 157-167.	0.6	103
23	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C9</i> and <i>HLA-B</i> Genotypes and Phenytoin Dosing: 2020 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 302-309.	2.3	102
24	Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 710-727.	1.3	100
25	Role of active metabolites in the use of opioids. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 121-139.	0.8	95
26	Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 217-227.	2.3	78
27	Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. <i>Pain</i> , 2006, 120, 267-275.	2.0	78
28	Pharmacokinetics and Bioavailability of Cimetidine in Gastric and Duodenal Ulcer Patients. <i>Clinical Pharmacokinetics</i> , 1980, 5, 84-94.	1.6	76
29	In Vitro–In Vivo Extrapolation Predicts Drug–Drug Interactions Arising from Inhibition of Codeine Glucuronidation by Dextropropoxyphene, Fluconazole, Ketoconazole, and Methadone in Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 609-618.	1.3	71
30	Inhibiting the TLR4–MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. <i>British Journal of Pharmacology</i> , 2012, 165, 1319-1329.	2.7	70
31	Pilot dose–response trial of i.v. ketamine in treatment-resistant depression. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 579-584.	1.3	70
32	Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 742-755.	1.1	66
33	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 570-584.	1.1	66
34	Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial. <i>Journal of Psychopharmacology</i> , 2018, 32, 397-407.	2.0	66
35	Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. <i>Addiction</i> , 2004, 99, 940-945.	1.7	65
36	The Relationship Between Mood State and Plasma Methadone Concentration in Maintenance Patients. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 78-84.	0.7	64

#	ARTICLE	IF	CITATIONS
37	Increased Absorption of Digoxin from the Human Jejunum Due to Inhibition of Intestinal Transporter-Mediated Efflux. <i>Clinical Pharmacokinetics</i> , 2007, 46, 777-785.	1.6	64
38	Kinetics and inhibition of the formation of 6β -naltrexol from naltrexone in human liver cytosol. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 465-471.	1.1	59
39	Morphine formation from codeine in rat brain: A possible mechanism of codeine analgesia. <i>Life Sciences</i> , 1990, 46, 1067-1074.	2.0	58
40	Risk Assessment and Communication Tools for Genotype Associations with Multifactorial Phenotypes: The Concept of "Edge Effect" and Cultivating an Ethical Bridge between Omics Innovations and Society. <i>OMICS A Journal of Integrative Biology</i> , 2009, 13, 43-61.	1.0	58
41	Naloxone-precipitated morphine withdrawal behavior and brain IL-1 β expression: Comparison of different mouse strains. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1223-1232.	2.0	57
42	Application of Stable Labelled Drugs in Clinical Pharmacokinetic Investigations. <i>Clinical Pharmacokinetics</i> , 1982, 7, 490-507.	1.6	56
43	Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 51, 379-387.	2.3	54
44	Effect of cimetidine on renal and hepatic drug elimination: Studies with triamterene. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 40, 400-407.	2.3	52
45	Cimetidine plasma concentration-response relationships. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 29, 744-748.	2.3	51
46	<i>CYP2B6</i> allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 276-284.	1.1	51
47	Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. <i>Drug and Alcohol Dependence</i> , 2003, 72, 85-94.	1.6	50
48	The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans. <i>Biopharmaceutics and Drug Disposition</i> , 1990, 11, 507-518.	1.1	48
49	The effects of a single mild dose of morphine on chemoreflexes and breathing in obstructive sleep apnea. <i>Respiratory Physiology and Neurobiology</i> , 2013, 185, 526-532.	0.7	45
50	The <i>CYP2B6</i> Allele Significantly Alters the N-Demethylation of Ketamine Enantiomers In Vitro. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1264-1272.	1.7	45
51	Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 562-71.	1.0	45
52	Plasma Concentrations and Renal Clearance of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Cancer Patients Receiving Morphine. <i>Clinical Pharmacokinetics</i> , 1993, 24, 413-420.	1.6	44
53	Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 609-617.	1.1	44
54	A novel animal model of graded neuropathic pain: Utility to investigate mechanisms of population heterogeneity. <i>Journal of Neuroscience Methods</i> , 2010, 193, 47-53.	1.3	44

#	ARTICLE	IF	CITATIONS
55	In vivo and in vitro potency studies of 6- α -naltrexol, the major human metabolite of naltrexone. <i>Addiction Biology</i> , 2002, 7, 219-225.	1.4	43
56	Pharmacogenomics of methadone maintenance treatment. <i>Pharmacogenomics</i> , 2014, 15, 1007-1027.	0.6	43
57	Codeine o-demethylation: Rat strain differences and the effects of inhibitors. <i>Biochemical Pharmacology</i> , 1991, 41, 757-762.	2.0	42
58	Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 185-194.	0.7	42
59	Primary and secondary oxidative metabolism of dextromethorphan. <i>Biochemical Pharmacology</i> , 1993, 45, 833-839.	2.0	41
60	RENAL TRANSPORT OF DRUGS: SPECIFICITY AND MOLECULAR MECHANISMS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1996, 23, 986-989.	0.9	41
61	Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 131-140.	2.3	41
62	Rectal Administration of Metronidazole Provides Therapeutic Plasma Levels in Postoperative Patients. <i>New England Journal of Medicine</i> , 1981, 305, 1569-1570.	13.9	40
63	Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 869-876.	0.7	39
64	ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 53.	0.4	39
65	Elimination of amphotericin B in impaired renal function. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 34, 248-253.	2.3	37
66	Pharmacogenetics of Opioid Response. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 125-127.	2.3	36
67	Simultaneous determination of codeine, norcodeine and morphine in biological fluids by high-performance liquid chromatography with fluorescence detection. <i>Biomedical Applications</i> , 1989, 491, 367-378.	1.7	34
68	Long-Lasting Effects of a Single Subcutaneous Dose of Ketamine for Treating Melancholic Depression: A Case Report. <i>Biological Psychiatry</i> , 2014, 76, e1-e2.	0.7	32
69	Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors?. <i>BMJ Open</i> , 2015, 5, e006818-e006818.	0.8	32
70	Bioequivalence of Four 100mg Oral Aspirin Formulations in Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 1991, 21, 394-399.	1.6	31
71	The effect of old age on the disposition and antinociceptive response of morphine and morphine-6 β -glucuronide in the rat. <i>Pain</i> , 1997, 71, 199-205.	2.0	31
72	Validation of an LC-MS/MS Method to Measure Tacrolimus in Rat Kidney and Liver Tissue and Its Application to Human Kidney Biopsies. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 617-623.	1.0	31

#	ARTICLE	IF	CITATIONS
73	Inside the isomers: the tale of chiral switches. Australian Prescriber, 2004, 27, 47-49.	0.5	31
74	Neuropsychological and Pharmacokinetic Assessment of Hospice Inpatients Receiving Morphine. Journal of Pain and Symptom Management, 1998, 16, 112-120.	0.6	29
75	The effect of acute morphine on obstructive sleep apnoea: a randomised double-blind placebo-controlled crossover trial. Thorax, 2019, 74, 177-184.	2.7	29
76	The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to <i>VKORC1</i> genotype. British Journal of Clinical Pharmacology, 2013, 75, 208-216.	1.1	28
77	GLUCURONIDATION OF DIHYDROCODEINE BY HUMAN LIVER MICROSOMES AND THE EFFECT OF INHIBITORS. Clinical and Experimental Pharmacology and Physiology, 1998, 25, 266-270.	0.9	27
78	Evaluation of levo-alpha-acetylmethadol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis. Drug and Alcohol Dependence, 2004, 76, 63-72.	1.6	27
79	A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol. BMJ Open, 2017, 7, e018100.	0.8	27
80	<i>CYP3A5</i> and <i>ABCB1</i> Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 320-326.	1.2	27
81	Effects of Electroacupuncture on Opioid Consumption in Patients with Chronic Musculoskeletal Pain: A Multicenter Randomized Controlled Trial. Pain Medicine, 2019, 20, 397-410.	0.9	27
82	Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin. Pharmaceutical Research, 1995, 12, 149-154.	1.7	26
83	Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. Pain, 2016, 157, 2458-2466.	2.0	26
84	Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. Pain Medicine, 2019, 20, 119-128.	0.9	26
85	CYP2B6, CYP2D6, and CYP3A4 Catalyze the Primary Oxidative Metabolism of Perhexiline Enantiomers by Human Liver Microsomes. Drug Metabolism and Disposition, 2007, 35, 128-138.	1.7	25
86	New insights into the renal secretion of drugs. Trends in Pharmacological Sciences, 1987, 8, 354-357.	4.0	24
87	Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clinical Pharmacology and Therapeutics, 2004, 76, 230-238.	2.3	24
88	Cerebral kinetics of oxycodone in conscious sheep. Journal of Pharmaceutical Sciences, 2006, 95, 1666-1676.	1.6	24
89	Adoptive transfer of peripheral immune cells potentiates allodynia in a graded chronic constriction injury model of neuropathic pain. Brain, Behavior, and Immunity, 2011, 25, 503-513.	2.0	24
90	Methadone inhibits CYP2D6 and UGT2B7/2B4 <i>in vivo</i> : a study using codeine in methadone- and buprenorphine-maintained subjects. British Journal of Clinical Pharmacology, 2012, 73, 786-794.	1.1	24

#	ARTICLE	IF	CITATIONS
91	(R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 895-902.	1.1	23
92	Quantification of the O- and N-demethylated metabolites of hydrocodone and oxycodone in human liver microsomes using liquid chromatography with ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 785, 81-88.	1.2	22
93	Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 835-841.	1.1	22
94	CONCENTRATION-EFFECT RELATIONSHIPS OF MORPHINE AND MORPHINE-6?-GLUCURONIDE IN THE RAT. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1997, 24, 359-364.	0.9	21
95	Alcohol-induced sedation and synergistic interactions between alcohol and morphine: A key mechanistic role for Toll-like receptors and MyD88-dependent signaling. <i>Brain, Behavior, and Immunity</i> , 2015, 45, 245-252.	2.0	21
96	Metronidazole pharmacokinetics in patients with acute renal failure. <i>Journal of Antimicrobial Chemotherapy</i> , 1984, 13, 183-189.	1.3	20
97	Determination of endogenous concentrations of N1-methylnicotinamide in human plasma and urine by high-performance liquid chromatography. <i>Analytical Biochemistry</i> , 1990, 187, 160-165.	1.1	20
98	Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 404-413.	1.1	20
99	Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl. <i>PLoS ONE</i> , 2015, 10, e0137179.	1.1	20
100	High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2163-2169.	1.1	19
101	Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 945-946, 171-177.	1.2	18
102	Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 175-179.	1.1	17
103	Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 536-541.	1.1	17
104	Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 832, 114-120.	1.2	17
105	Switching between Methadone and Morphine for Maintenance Treatment of Opioid Dependence: Impact on Pain Sensitivity and Mood Status. <i>American Journal on Addictions</i> , 2006, 15, 311-315.	1.3	17
106	Antinociceptive effects of high dose remifentanil in male methadone-maintained patients. <i>European Journal of Pain</i> , 2008, 12, 926-933.	1.4	17
107	Flexible dosing of Tincture of Opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 640-7.	1.1	17
108	Association of Innate Immune Single-Nucleotide Polymorphisms with the Electroencephalogram During Desflurane General Anaesthesia. <i>Journal of Molecular Neuroscience</i> , 2014, 52, 497-506.	1.1	17

#	ARTICLE	IF	CITATIONS
109	Direct determination of codeine-6-glucuronide in plasma and urine using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. <i>Biomedical Applications</i> , 1989, 493, 313-324.	1.7	16
110	Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 1113-1120.	0.8	16
111	The effect of methadone on emotional reactivity. <i>Addiction</i> , 2012, 107, 388-392.	1.7	16
112	CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 977-985.	1.6	16
113	The Prevalence, Impact, and Risk Factors for Persistent Pain After Breast Cancer Surgery in a New Zealand Population. <i>Pain Medicine</i> , 2019, 20, 1803-1814.	0.9	16
114	Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis. <i>Pharmacogenomics and Personalized Medicine</i> , 2009, 2, 9-19.	0.4	16
115	CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. <i>Xenobiotica</i> , 2004, 34, 875-887.	0.5	15
116	Stereoselective Quantification of Methadone and a d6-labeled Isotopomer Using High Performance Liquid Chromatography-Atmospheric Pressure Chemical Ionization Mass-Spectrometry: Application to a Pharmacokinetic Study in a Methadone Maintained Subject. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 559-567.	1.0	15
117	Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 326-335.	1.1	15
118	Measurement of Cyclosporine A in Rat Tissues and Human Kidney Transplant Biopsies—A Method Suitable for Small ($\leq 1\text{ mg}$) Samples. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 688-693.	1.0	15
119	Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2433-2442.	1.1	15
120	The Absorption and Disposition of Enoxacin in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 707-713.	1.0	14
121	In vitro opioid induced proliferation of peripheral blood immune cells correlates with in vivo cold pressor pain tolerance in humans: a biological marker of pain tolerance. <i>Pain</i> , 2004, 110, 751-755.	2.0	13
122	(S)-(+)-methadone is more immunosuppressive than the potent analgesic (R)-(-)-methadone. <i>International Immunopharmacology</i> , 2004, 4, 1525-1530.	1.7	13
123	The future of thiopurine pharmacogenomics. <i>Pharmacogenomics</i> , 2012, 13, 1549-1552.	0.6	13
124	Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib. <i>Xenobiotica</i> , 2016, 46, 278-287.	0.5	13
125	Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3901-3909.	1.1	13
126	Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 843, 302-309.	1.2	12

#	ARTICLE	IF	CITATIONS
127	Genomic testing as a tool to optimise drug therapy. Australian Prescriber, 2017, 40, 101-104.	0.5	12
128	Toll-Like Receptors change morphine-induced antinociception, tolerance and dependence: studies using male and female TLR and Signalling gene KO mice. Brain, Behavior, and Immunity, 2022, . .	2.0	12
129	A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. Australian and New Zealand Journal of Psychiatry, 2023, 57, 362-378.	1.3	12
130	Sensitive High-Performance Liquid Chromatographic Assay for Determination of Amiloride in Biologic Fluids Using an Ion-Pair Extraction Method. Therapeutic Drug Monitoring, 1988, 10, 463-468.	1.0	11
131	A phase I study of the GM-CSF antagonist E21R. Cancer Chemotherapy and Pharmacology, 2002, 50, 171-178.	1.1	9
132	Advances in drug metabolism and pharmacogenetics research in Australia. Pharmacological Research, 2017, 116, 7-19.	3.1	9
133	Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenetics and Genomics, 2019, 29, 9-17.	0.7	9
134	Relationship between 4,5-epoxymorphinan structure and in vitro modulation of cell proliferation. European Journal of Pharmacology, 2004, 494, 251-262.	1.7	8
135	The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio.. Experimental and Clinical Psychopharmacology, 2009, 17, 146-153.	1.3	8
136	Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. British Journal of Clinical Pharmacology, 2008, 65, 347-354.	1.1	7
137	Gastric acid inhibition and oxmetidine kinetics in duodenal ulcer. Clinical Pharmacology and Therapeutics, 1982, 31, 501-507.	2.3	6
138	Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. British Journal of Clinical Pharmacology, 2004, 57, 456-463.	1.1	6
139	Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. BMC Anesthesiology, 2014, 14, 33.	0.7	6
140	Increase in PAS-induced neuroplasticity after a treatment course of intranasal ketamine for depression. Report of three cases from a placebo-controlled trial. Comprehensive Psychiatry, 2017, 73, 31-34.	1.5	6
141	Pharmacogenomics in Papua New Guineans. Pharmacogenetics and Genomics, 2018, 28, 153-164.	0.7	6
142	Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?. Therapeutic Drug Monitoring, 2019, 41, 528-532.	1.0	6
143	Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. Clinical and Translational Science, 2021, 14, 2521-2531.	1.5	6
144	Characterisation of the in vitro modulation of splenocyte proliferation by non-4,5-epoxymorphinan opioids. International Immunopharmacology, 2005, 5, 1713-1722.	1.7	5

#	ARTICLE	IF	CITATIONS
145	Fluctuations in (R,S)-methadone pharmacokinetics and response among long-term methadone maintenance patients. <i>Addiction Biology</i> , 2006, 11, 170-174.	1.4	5
146	Adding the "medicines"™ back into personalized medicine to improve cancer treatment outcomes. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 929-931.	1.1	5
147	Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1015-1020.	1.1	5
148	Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment-Resistant Depression. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 720-729.	2.3	5
149	Effect of variations in urine pH and flow rate on cimetidine renal disposition in man. <i>Biopharmaceutics and Drug Disposition</i> , 1985, 6, 345-349.	1.1	4
150	Innate Immune and Neuronal Genetic Markers Are Highly Predictive of Postoperative Pain and Morphine Patient-Controlled Analgesia Requirements in Indian but Not Chinese or Malay Hysterectomy Patients. <i>Pain Medicine</i> , 2021, 22, 2648-2660.	0.9	4
151	Blood-brain equilibration kinetics of levo- α -acetyl-methadol using a chronically instrumented sheep preparation. <i>British Journal of Pharmacology</i> , 2006, 147, 209-217.	2.7	3
152	Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats. <i>Xenobiotica</i> , 2015, 45, 3-9.	0.5	3
153	Enantioselectivity in the tissue distribution of perhexiline contributes to different effects on hepatic histology and peripheral neural function in rats. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00406.	1.1	3
154	Conference report: pharmacogenomics in special populations at WCP2018. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 467-475.	1.1	3
155	Pharmacogenetics of statin intolerance. <i>Internal Medicine Journal</i> , 2020, 50, 506-507.	0.5	3
156	New pharmacological perspectives and therapeutic options for opioids: Differences matter. <i>Anaesthesia and Intensive Care</i> , 2022, , 0310057X2110638.	0.2	3
157	Comments on Cooper et al.'s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 489-489.	1.3	2
158	No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation. <i>Frontiers in Pharmacology</i> , 2020, 10, 1686.	1.6	2
159	Drug disposition and dosing in hepatic disease. <i>Medical Journal of Australia</i> , 1986, 145, 284-289.	0.8	2
160	Prescribing for the patient with renal disease. <i>Medical Journal of Australia</i> , 1986, 145, 210-215.	0.8	1
161	Editors' pick 2011. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 4-8.	1.1	1
162	Editors' report for 2014, November 2014. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 4-5.	1.1	1

#	ARTICLE	IF	CITATIONS
163	Editors' pick 2014. British Journal of Clinical Pharmacology, 2015, 79, 354-356.	1.1	1
164	The effect of acute morphine on sleep in male patients suffering from sleep apnea: Is there a genetic effect? An RCT Study. Journal of Sleep Research, 2020, 30, e13249.	1.7	1
165	Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. Pain Medicine, 2020, 21, 2007-2008.	0.9	1
166	Instability of Efavirenz Metabolites Identified During Method Development and Validation. Journal of Pharmaceutical Sciences, 2021, 110, 3362-3366.	1.6	1
167	Changes in Methadone Concentration, Opioid Effects, and Opioid Withdrawal During Induction Onto Maintenance Treatment. Addictive Disorders and Their Treatment, 2004, 3, 122-128.	0.5	0
168	Editors' pick 2010. British Journal of Clinical Pharmacology, 2011, 71, 3-6.	1.1	0
169	Editors' report, November 2011. British Journal of Clinical Pharmacology, 2012, 73, 159-160.	1.1	0
170	Editors' pick 2012. British Journal of Clinical Pharmacology, 2013, 75, 1-6.	1.1	0
171	Editors' Report, 2012. British Journal of Clinical Pharmacology, 2013, 75, 301-302.	1.1	0
172	Does Intraoperative Ketamine Attenuate Inflammatory Reactivity Following Surgery? A Systematic Review and Meta-Analysis. Survey of Anesthesiology, 2013, 57, 90-91.	0.1	0
173	<scp>BJCP</scp> 40th anniversary: moving forward, looking back. British Journal of Clinical Pharmacology, 2014, 78, 1175-1184.	1.1	0
174	Editors' pick 2013. British Journal of Clinical Pharmacology, 2014, 77, 228-232.	1.1	0
175	Editors' report, November 2013. British Journal of Clinical Pharmacology, 2014, 77, 401-402.	1.1	0
176	Clinically Significant Interactions with Anti-addiction Agents. , 2016, , 565-577.		0
177	Editors' Report for 2015, December 2015. British Journal of Clinical Pharmacology, 2016, 81, 6-7.	1.1	0
178	Impaired psychomotor function and plasma methadone and levo-alpha-acetylmethadol (LAAM) concentrations in opioid-substitution patients.. Experimental and Clinical Psychopharmacology, 2017, 25, 223-233.	1.3	0
179	A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression " the way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 2019, 33, 260-261.	2.0	0
180	Pharmacogenetics in Palliative Care. , 2010, , 115-125.		0

#	ARTICLE	IF	CITATIONS
181	Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy, Blood, 2011, 118, 3501-3501.	0.6	0
182	Pharmacogenomics in the Oceania region: Precision medicine challenges. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY48-1.	0.0	0